Merck appoints Maya Martinez-Davis as global head of oncology
April 14, 2016Medical Communications Merck, maya martinez-davis, oncology
Merck has announced the appointment of Maya Martinez-Davis as the new global head of oncology at the German-based company. In …
Merck says US FDA to review its Keytruda for head & neck cancer
April 14, 2016Research and Development, Sales and Marketing Cancer Immunotherapy, Merck & Co, US FDA, keytruda
The US Food and Drug Administration has accepted Merck & Co’s (NYSE: MRK) supplemental biologics license application (sBLA) for its immunotherapy cancer …
Zika causes microcephaly and other birth defects, says CDC
April 14, 2016Medical Communications, Research and Development CDC, Zika, Zika virus, birth defects, microcephaly
The US Centers for Disease Control and Prevention has concluded that the Zika virus is a cause of microcephaly and …
Merck says its Zepatier showed better efficacy and safety compared with competition in Phase III trials
April 14, 2016Research and Development, Sales and Marketing Gilead, HCV, Merck & Co, Zepatier
US pharma giant Merck (NYSE: MRK) on Thursday said late-stage trials for its Zepatier (elbasvir and grazoprevir) to treat chronic …
AbbVie announces positive Phase III results in hepatitis C drug
April 14, 2016Manufacturing and Production, Research and Development AbbVie, hepatitis, phase III
AbbVie (NYSE: ABBV) has announced positive results from their Phase III evaluating the combination of Viekirax and Exviera, with or …
NICE issues new guidance on the safer use of controlled drugs
April 13, 2016Medical Communications NICE, controlled drugs, guidance
The National Institute for Health and Care Excellence (NICE) has issued guidance bringing together legislation and existing advice on the …
Sanofi reinforces collaboration with Stevenage Bioscience Catalyst with partnering office
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Sanofi, Stevenage Bioscience Catalyst, academia, industry, partnership, pharma, stevenage
Sanofi has reinforced its collaboration with Stevenage Bioscience Catalyst with the opening of a new partnering office. This office will …
Bristol-Myers Squibb cancer immunotherapy Opdivo approved in EU
April 13, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, EU, NICE, approval, immunotherapy, opdivo
Bristol-Myers Squibb has announced that its potentially life-extending cancer immunotherapy, Opdivo (nivolumab), has been approved by the European Commission to …
US FDA committee recommends against fast-track approval of Clovis’ cancer drug, asks for more data
April 13, 2016Medical Communications, Research and Development
Shares in Clovis Oncology Inc (Nasdaq: CLVS) closed down 5.4% Tuesday after the US Food and Drug Administration advisory committee recommended …
Structure of Zika virus revealed in new study
April 13, 2016Research and Development NIH, Purdue, Zika, glycoprotein, structure
Researchers have examined the structure of the Zika virus in a new study and found that is broadly similar to …
FDA accepts biologics license application for MSD’s allergy immunotherapy drug
April 13, 2016Research and Development, Sales and Marketing MSD, Merck, allergy, dust mite, house, immunotherapy, mk-8237
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has accepted for review the biologics license application …
Boehringer Ingelheim’s Giotrif significantly lowers lung cancer progression in Phase II trials
April 13, 2016Research and Development AstraZeneca, Boehringer Ingelheim, Iressa, giotrif, lung cancer
German drugmaker Boehringer Ingelheim on Wednesday said a mid-stage study has shown its cancer drug Giotrif (afatinib) reduced the risk …
Valeant bondholders issue notice to default
April 13, 2016Research and Development, Sales and Marketing Valeant, bondholders, default, fears, possibility
Valeant (NYSE: VRX) has issued a statement detailing plans from some of its bondholders to call a default because of …
Focus: Ovarian cancer and the case of elusive cure
April 12, 2016Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer
Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …
EUSA Pharma acquires global rights to oncology support drug
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eusa Pharma, acroral, acroral tab, global rights, oncology
EUSA Pharma has announced the acquisition of global rights to oncology support care product, Arcoral Tab, from Arcoral Pharma.
Regeneron agrees six-year $75 million upfront licencing deal with Intellia for gene technology
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing IPO, Intellia Therapeutics, Licencing, Regeneron Pharmaceuticals, crispr, deal, gene editing, genetics
Regeneron Pharmaceuticals Inc (Nasdaq: REGN) on Tuesday said it has signed a six-year licencing deal with biotech firm Intellia Therapeutics …
KaloBios announces new affordable pricing model, refuses to engage in “price gouging”
April 12, 2016Manufacturing and Production, Sales and Marketing CEO, Drug pricing, KaloBios, Martin Shkreli, Shkreli, affordable, price gouging, price model, responsible
Price gouging has become synonymous with drug costs in the US, with the infamous Martin Shkreli and troubled Valeant becoming …
Clinical studies point to consistent efficacy in AstraZeneca’s treatment for drug-resistance bacteria
April 12, 2016Manufacturing and Production, Research and Development AstraZeneca, avibactam, ceftazidime, gram resistant
AstraZeneca has presented results from a series of trials which show the consistent efficacy of investigational antibiotic, ceftazidime-avibactam (CAZ-AVI) in …
Roche’s Venclexta gets accelerated approval from US FDA for chronic lymphocytic leukemia
April 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing AbbVie, Roche, US FDA, Venclexta, chronic lymphocytic leukemia
Swiss drug firm Roche (SIX: ROG) on Tuesday said the US Food and Drug Administration (FDA) has granted accelerated approval …
Insys Therapeutics sees revenue from Subsys at $61-$62 million; shares plunge 21%
April 11, 2016Business Services, Manufacturing and Production, Sales and Marketing Insys Therapeutics, Stock Price, Subsys, opioids, pain drug
Insys Therapeutics Inc (Nasdaq: INSY) stock plunged nearly 21% Monday after the company said sales for its pain drug will …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
